Business Context and Reporting Period
The provided filing is Vallon Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2020, not GRI Bio, Inc. Vallon was a clinical-stage biopharmaceutical company focused on central nervous system disorders. Its lead candidate was ADAIR, an abuse-deterrent immediate-release dextroamphetamine formulation for ADHD and narcolepsy; ADMIR, an abuse-deterrent Ritalin formulation, was in early development.
Vallon had no approved products or product sales. ADAIR development was intended to proceed under the FDA’s Section 505(b)(2) pathway. A pivotal intranasal human abuse study began enrollment in the fourth quarter of 2020.
Financial Performance and Position
| Metric | 2020 | 2019 |
|---|---|---|
| License revenue from related party | $100,000 | $0 |
| Research and development expense | $3.707 million | $1.882 million |
| General and administrative expense | $1.181 million | $1.272 million |
| Loss from operations | $4.788 million | $3.154 million |
| Net loss | $4.822 million | $3.464 million |
| Net loss per share | $1.07 | $0.98 |
| Net cash used in operating activities | $3.706 million | $2.884 million |
| Cash and cash equivalents at year-end | $109,000 | $3.821 million |
At December 31, 2020, total assets were $955,000, total liabilities were $2.409 million, and stockholders’ deficit was $1.454 million. Current liabilities were $2.225 million, including $1.226 million of accounts payable and $847,000 of accrued expenses.
The company had a $61,000 Paycheck Protection Program note outstanding at year-end, which was forgiven in January 2021. Finance lease liabilities totaled $275,000 at year-end, including $105,000 current and $170,000 non-current. The filing does not report substantial conventional funded debt beyond the PPP note and finance lease.
No income tax expense or benefit was recognized. The company reported federal, state and local net operating loss carryforwards of approximately $11.6 million, subject to potential Section 382 limitations and a full valuation allowance.
Material Changes Versus 2019
- Revenue increased from zero to $100,000, consisting of a related-party license payment under the Medice agreement.
- Research and development expense increased $1.825 million, primarily due to ADAIR registration development, manufacturing activities, ADMIR formulation work, stock compensation and Medice-related development costs.
- General and administrative expense decreased $91,000, mainly because of lower legal, travel and conference costs.
- Net loss increased $1.358 million to $4.822 million.
- Operating cash use increased $822,000 to $3.706 million, while cash declined $3.712 million during the year.
- The 2019 convertible notes and related derivative liability had converted into common stock in July 2019; therefore, no derivative revaluation was recorded in 2020 and interest expense declined to $34,000 from $197,000.
Guidance, Outlook, Risks and Unusual Items
Management expected continuing operating losses and negative operating cash flow for at least the next several years. As of December 31, 2020, cash was only $109,000, and the independent auditor included a going-concern explanatory paragraph. Management stated that additional capital would be required to continue operations and complete ADAIR development.
Subsequent to year-end, Vallon raised $350,000 through convertible notes and completed a February 2021 initial public offering of 2.25 million shares at $8.00 per share. Net IPO proceeds were approximately $15.5 million. Management estimated that approximately $15.9 million of combined net proceeds from the IPO and 2021 notes would fund operations into the third quarter of 2022, although this estimate was subject to significant uncertainty and would not fund all development and commercialization requirements.
On January 6, 2020, Vallon granted Medice, an affiliate of a principal stockholder and represented on the board, an exclusive European license for ADAIR. The agreement provided for a minimal upfront payment, potential milestone payments of up to $6.3 million and tiered royalties of 10% to 20% on annual net sales.
Key risks include failure to obtain FDA or foreign regulatory approval, failure of ADAIR’s pivotal abuse study, inability to obtain abuse-deterrent labeling, clinical or preclinical delays, controlled-substance restrictions, dependence on third-party manufacturers and CROs, limited commercial infrastructure, reliance on additional financing, intellectual-property challenges, reimbursement pressure and COVID-19-related disruptions.
The company disclosed material weaknesses in internal control over financial reporting related to inadequate segregation of duties, insufficient documentation and controls over certain transactions. Management had begun remediation but could not assure when or whether the weaknesses would be fully remediated. No material legal proceedings were pending.
Important Facts for Investors to Verify
- Verify the company identity: the supplied filing is for Vallon Pharmaceuticals, Inc., while the request identifies GRI Bio, Inc.
- Confirm the going-concern qualification, year-end cash of $109,000 and the timing and net proceeds of the February 2021 IPO.
- Review ADAIR’s pivotal intranasal abuse study status, results and the FDA’s position on the proposed 505(b)(2) pathway and abuse-deterrent labeling.
- Assess reliance on Medice, including related-party governance, milestone economics, royalty rates and European development obligations.
- Review the material weaknesses in internal control and management’s remediation progress.
- Confirm outstanding finance lease obligations, the forgiveness of the PPP note and the company’s projected funding runway.